利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

162 条记录 (耗时 0.038 秒)

    Process for preparing halogenoalkylnitrates
    7.
    发明授权
    Process for preparing halogenoalkylnitrates 失效
    卤代烷基硝酸盐的制备方法

    公开(公告)号：US07745496B2

    公开(公告)日：2010-06-29

    申请号：US11667970

    申请日：2005-11-09

    申请人： Romano Rivolta ,  Peter Finlander

    发明人： Romano Rivolta ,  Peter Finlander

    IPC分类号： A61K31/02 ,  C07C291/02

    CPC分类号： C07C203/04

    摘要： A process for preparing a compound of formula (I) X-(CH2)n-ONO2  (I) wherein: X is a halogen atom selected from Cl, Br, I; n is an integer from 3 to 6; said process comprising the slow addition of a compound of formula (II) X-(CH2)n-OH  (II) wherein X and n are as defined above to a nitrating agent selected from the group consisting of concentrated nitric acid/concentrated sulfuric acid (sulfonitric mixture), nitric acid alone, NaNO2 in trifluoroacetic acid, nitronium salts such as NO2BF4 and an organic solvent selected from the group consisting of CH2Cl2, CHCl3, CCl4, perfluorohexane, perfluoroheptane. The invention refers also to solutions containing: a compound of general formula (I) and a solvent selected from the group consisting of CH2Cl2, CHCl3, CCl4, perfluorohexane, perfluoroheptane, characterized in that the compound of formula (I) is present in a concentration not higher than 20% by weight.

    摘要翻译： 制备式（I）化合物的方法X-（CH 2）n -ONO 2（I）其中：X是选自Cl，Br，I的卤素原子; n为3〜6的整数， 所述方法包括将其中X和n如上定义的式（II）的化合物（II）X-（CH 2）n -OH（II）缓慢加入到选自浓硝酸/浓硫酸 （磺化混合物），单独的硝酸，三氟乙酸中的NaNO 2，硝酸盐如NO 2 BO 4和选自CH 2 Cl 2，CHCl 3，CCl 4，全氟己烷，全氟庚烷的有机溶剂。 本发明还涉及包含通式（I）的化合物和选自CH 2 Cl 2，CHCl 3，CCl 4，全氟己烷，全氟庚烷的溶剂的溶液，其特征在于式（I）化合物以浓度 不高于20重量％。

    Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use
    8.
    发明申请
    Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use 审中-公开
    血管紧张素转换酶抑制剂，组合物和使用方法的有机一氧化氮供体盐

    公开(公告)号：US20080293678A1

    公开(公告)日：2008-11-27

    申请号：US11886461

    申请日：2006-03-17

    申请人： David S. Garvey

    发明人： David S. Garvey

    IPC分类号： C07D271/08 ,  C07D207/00 ,  A61K31/40 ,  A61K31/675 ,  C07F9/572 ,  C07D209/02 ,  A61K31/403 ,  A61K31/407 ,  C07D495/10 ,  C07D223/14 ,  A61K31/55 ,  A61K31/551 ,  A61K31/554 ,  C07D487/04 ,  C07D281/02 ,  C07D233/00 ,  A61K31/4166 ,  A61K31/47 ,  A61P9/00 ,  C07D413/00 ,  C07D217/00 ,  A61K31/216 ,  C07C229/00 ,  C07D295/00 ,  A61K31/5375 ,  A61K31/44 ,  C07D213/56 ,  C07C291/02 ,  A61K31/04 ,  A61K31/41

    CPC分类号： C07D207/16

    摘要： The invention describes compositions and kits comprising at least qrie organic nitric oxide enhancing salt of an angiotensin converting enzyme inhibitor, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin converting enzyme inhibitors are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

    摘要翻译： 本发明描述了包含血管紧张素转换酶抑制剂的至少有机一氧化氮增强盐，和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的组合物和试剂盒。 本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; Q）治疗骨质疏松症; （k）治疗肾病; （l）治疗外周血管疾病; （m）治疗门静脉高压; （n）治疗眼科疾病; （o）治疗代谢综合征; 和（p）治疗高脂血症。 与血管紧张素转换酶抑制剂形成盐的有机一氧化氮增强化合物是有机硝酸盐，有机亚硝酸盐，亚硝基硫醇，硫堇啶，硫堇酸盐，非硝酸盐，杂环一氧化氮供体和/或氮氧化物。 杂环一氧化氮供体是呋喃糖，苏氨酸，氧杂三唑-5-酮和/或氧杂三唑-5-亚胺。